de la Roche M et al. – BCL9 is required for efficient beta-catenin-mediated transcription in human cell lines with an active Wnt pathway, including colorectal cancer cells, indicating its potential as a drug target in colorectal cancer Methods
Study of the function of overexpression of dominant-negative forms of BCL9, and RNAi-mediated depletion in human cell lines with elevated Wnt pathway activity, including colorectal cancer cells
Results
BCL9 is required for efficient beta-catenin-mediated transcription in Wnt-stimulated HEK 293 cells, and in the SW480 colorectal cancer cell line whose Wnt pathway is active due to APC mutation
The function of dominant-negative mutants of BCL9 depends on its beta-catenin ligand but and an unknown ligand of its C-terminus
BCL9 and B9L are both Wnt-inducible genes, hyperexpressed in colorectal cancer cell lines, as part of a positive feedback loop
See all
